Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;9(5):1167-1169.
doi: 10.21037/gs.2020.03.12.

Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?

Pankaj G Roy  1 , Didier Verhoeven  2
Affiliations
Editorial

Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?

Pankaj G Roy et al. Gland Surg. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs.2020.03.12). The authors have no conflicts of interest to declare.

Comment on

References

    1. Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol 2020;6:e193692. - PMC - PubMed
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018;19:27-39. 10.1016/S1470-2045(17)30777-5 - DOI - PMC - PubMed
    1. Prowell TM, Beaver JA, Pazdur R. Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer. N Engl J Med 2019;380:612-5. 10.1056/NEJMp1900079 - DOI - PubMed
    1. Huober J, Holmes E, Baselga J, et al. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019;118:169-77. 10.1016/j.ejca.2019.04.038 - DOI - PubMed
    1. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32. 10.1016/S1470-2045(11)70336-9 - DOI - PubMed